Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Annual Price Revisions Should Continue in 2025 and Beyond: MOF Budget Examiner
May 15, 2024
- Japan Will Hew to 4-Minister Pact on Off-Year Revisions: Health Minister
May 15, 2024
- Purchasers Satisfied, Pharmacy Service “Appropriate” in Non-Prescription Pilot for Emergency Contraceptives
May 14, 2024
- Simplified Delisting to Be Allowed for Generics with Low Market Share from September: MHLW
May 13, 2024
- Posaconazole Added to List of Azole Antifungals Contraindicated for Xarelto on Bleeding Risks
May 13, 2024
- Shionogi COVID Jab Up for PAFSC Review Again after Efficacy Questions; Pfizer’s Zavicefta and Lots More on Roster
May 13, 2024
- Apply Elective Care Scheme to Original Biologics with Biosimilars: Professor to LDP
May 10, 2024
- Jaypirca, Prevymis Sail Through MHLW Panel Review; Avigan’s SFTS Use on Hold
May 10, 2024
- Researchers Urge Japan to Help Develop Domestic CAR-T Therapies
May 9, 2024
- Japan Needs Special Law on Medical Data to Allow Access Without Patient Consent: JPMA
May 8, 2024
- New LDP Project Team Boots Up for Healthcare Transformation
May 8, 2024
- H5N1 Pre-Pandemic Flu Vaccine Selected for Stockpiling in FY2024
May 7, 2024
- Diagnostics of Original Biologics Can Be Used for Biosimilars Too: MHLW
May 7, 2024
- MHLW Project Team Compiles Interim Proposal for Supporting Healthcare Startups
April 30, 2024
- Govt’s Healthcare Advisors Call for Bolstering AMED Staff: 2025-2029 Strategy
April 30, 2024
- Japan’s 1st Eylea Biosimilar Now in Line for Approval, AMD Dropped for Patent Reasons
April 30, 2024
- MHLW’s Generic Industry Panel to Call for 5-Year Intensive Reform Period
April 26, 2024
- Jaypirca, Prevymis, Relvar and More on MHLW Panel Agenda for May 9
April 26, 2024
- Regulation Panel’s Final Report Specifies Exemptions for All-Case PMS
April 25, 2024
- Japan Plans More Prompt Drug Approvals from 2025, Within 3 Weeks of Panel Nod
April 25, 2024
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…